Abstract:Abstract Background Select primary tauopathies exhibit MAPT (tau) mis‐splicing to produce an imbalance of 3R and 4R tau isoforms. Further, 3R and 4R tau isoforms deposit in neurons and glia in tauopathy patients, although it remains unclear whether tau isoform deposition is a cause or consequence of disease. Our group and others have identified a role for 4R tau in increased tau phosphorylation and aggregation, suggesting that 4R tau‐mediated mechanisms may influence disease. Therefore, therapeutic strategies targeted against 4R tau may be beneficial. Method We developed antisense oligonucleotides (ASOs) that enable control of 3R and 4R tau splicing without altering total tau levels in human tau‐expressing mice, primary mouse astrocytes, and astrocytes derived from human induced pluripotent stem cells (iPSCs). We quantified gene markers of astrocyte reactivity and measures of astrocyte function, including glutamate uptake and response to oxidative stress. Finally, we performed bulk RNAseq from mouse brain tissue following tau splicing manipulation. Result Increasing 4R tau in human tau mice and primary mouse astrocytes induced a neurotoxic gene signature, including evidence for complement pathway involvement. Astrocytes derived from iPSCs of tauopathy patients expressing the MAPT mutation IVS 10+16 (biases toward 4R tau expression) exhibited increased expression of genes associated with neurotoxicity, were vulnerable to oxidative stress, and had reduced glutamate uptake. 4R tau‐expressing astrocytes, including IVS 10+16 mutation carriers, promoted hyperexcitability characteristics in co‐cultured neurons compared to controls. Bulk RNAseq analysis supported isoform‐specific changes in gene expression. Conclusion Astrocytes appear particularly vulnerable to increased 4R tau in vivo and in vitro, inducing dysfunction that may leave neurons prone to hyperexcitability and degeneration. Although tau isoform imbalance toward greater 4R tau likely induces both neuronal and glial changes, tau‐mediated toxicity within astrocytes may reveal unique mechanisms of disease progression and targets for therapeutics.

Astrocyte senescence and SASP in neurodegeneration: tau joins the loop

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

The Difference in Gliosis Induced by Β-Amyloid and Tau Treatments in Astrocyte Cultures Derived from Senescence Accelerated and Normal Mouse Strains

Senescent Phenotype of Astrocytes Leads to Microglia Activation and Neuronal Death

Reactive astrocytes acquire neuroprotective as well as deleterious signatures in response to Tau and Aß pathology

The putative contribution of cellular senescence to driving tauopathies

Senescence, brain inflammation, and oligomeric tau drive cognitive decline in Alzheimer's disease: Evidence from clinical and preclinical studies

Dysfunction of astrocytes in senescence-accelerated mice SAMP8 reduces their neuroprotective capacity

Astrocyte senescence may drive alterations in GFAPα, CDKN2A p14ARF, and TAU3 transcript expression and contribute to cognitive decline

Aging-Related Tau Astrogliopathy in Aging and Neurodegeneration

Properties of Alzheimer’s disease brain-derived tau aggregates define tau processing by human astrocytes

Tau proteins and senescent Cells: Targeting aging pathways in Alzheimer's disease

Senescent Phenotype of Astrocytes Leads to Activation of BV2 Microglia and N2a Neuronal Cells Death

The Mechanistic Link Between Tau-Driven Proteotoxic Stress and Cellular Senescence in Alzheimer's Disease

Overexpression of pathogenic tau in astrocytes causes a reduction in AQP4 and GLT1, an immunosuppressed phenotype and unique transcriptional responses to repetitive mild TBI without appreciable changes in tauopathy

Astrocytic accumulation of tau fibrils isolated from Alzheimer's disease brains induces inflammation, cell-to-cell propagation and neuronal impairment

Contribution of the astrocytic tau pathology to synapse loss in progressive supranuclear palsy and corticobasal degeneration

Investigating 4R tau isoform imbalance as a mediator of astrocyte dysfunction in tauopathies

Senescent Astrocytes Derived from Human Pluripotent Stem Cells Reveal Age-Related Changes and Implications for Neurodegeneration

Soluble pathogenic tau enters brain vascular endothelial cells and drives cellular senescence and brain microvascular dysfunction in a mouse model of tauopathy

Tau protein modulates an epigenetic mechanism of cellular senescence in human SH-SY5Y neuroblastoma cells